Back to News
Market Impact: 0.42
Novartis Needs Board Shakeup and M&A Revamp, Investor Says
Source: Bloomberg
Healthcare & BiotechManagement & GovernanceM&A & RestructuringInvestor Sentiment & Positioning
Novartis shares plunged after three major clinical-trial setbacks, prompting shareholder Artisan Partners to call for a board shake-up. The activist investor also urged the Swiss drugmaker to improve its dealmaking, raising governance and strategic-execution concerns.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.58
Ticker Sentiment
APAM-0.15
NVS-0.80
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- ‘Total Meltdown’ in Riskiest Debt Unnerves Market: Credit Weekly
- AI funding fears rattle Wall Street. Here's how we're adjusting our portfolio
- Braskem creditors, shareholders near deal on $11bn debt restructuring
- Instacart reportedly discussed selling itself with DoorDash and Uber
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Document Search Enhancements, AI Enhancements, AI Actions, & Chat Export
- AI Vendor Landscape for Institutional Investment Teams